Radiopharm Theranostics Limited Sponsored ADR, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael Okunewitch from Maxim Group maintained a Buy rating on the stock and has a $12.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Michael Okunewitch has given his Buy rating due to a combination of factors that highlight Radiopharm Theranostics Limited’s strategic advancements and financial outlook. The company recently entered into a promising option agreement with Starpharma, which allows Radiopharm to potentially in-license a novel dendrimer-radio conjugate. This agreement underscores Radiopharm’s commitment to innovation and maintaining a competitive edge in the rapidly evolving radiopharmaceuticals sector.
Furthermore, the DEP technology from Starpharma, which Radiopharm is leveraging, is a validated platform known for its precision in drug delivery and targeting, crucial for the safety and efficacy of radiopharmaceuticals. Despite reporting a net loss for FY25, Radiopharm’s financial position remains stable with sufficient cash reserves to support ongoing development programs. The company’s future revenue projections, coupled with a strategic focus on innovative treatments, support the Buy rating with a 12-month price target of $12.
According to TipRanks, Okunewitch is an analyst with an average return of -7.6% and a 35.93% success rate. Okunewitch covers the Healthcare sector, focusing on stocks such as Lineage Therap, ATAI Life Sciences, and Ocugen.